Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment

Clinical Cancer Research

Volumn 16, Issue 8, 2010, Pages 2375-2382

  Dopeso, Higinio ^a   Mateo Lozano, Silvia ^a   Elez, Elena ^a   Landolfi, Stefania ^a   Pascual, Francisco Javier Ramos ^a   Hernández Losa, Javier ^a   Mazzolini, Rocco ^a   Rodrigues, Paulo ^a   Bazzocco, Sarah ^a   Carreras, Maria Josep ^a   Espín, Eloy ^a,b   Armengol, Manel ^a,b   Wilson, Andrew J ^c   Mariadason, John M ^d   Ramon Y Cajal, Santiago ^a   Tabernero, Josep ^a   Schwartz Jr , Simo ^a,b   Arango, Diego ^a,b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APRATAXIN; BIOLOGICAL MARKER; CAMPTOTHECIN; HISTIDINE; IRINOTECAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; DNA REPAIR; DRUG ACTIVITY; DRUG SENSITIVITY; FEMALE; GENETIC CODE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE I; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77951010997     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3275     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326
3. Petrelli N, Douglass HO, Jr., Herrera L, et al, Gastrointestinal Tumor Study Group. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-1426 (Pubitemid 19245111)
4. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047 (Pubitemid 30162806)
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345 (Pubitemid 38944402)
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342 (Pubitemid 38702844)
8. Saltz LB, Cox JV, Blanke C, et al, Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914
9. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-2096
10. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002;28:27-47. (Pubitemid 34679207)
11. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-4304 (Pubitemid 33096777)
12. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878 (Pubitemid 16211028)
13. Kohne CH, van Cutsem E, Wils J, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-4865 (Pubitemid 46223990)
14. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690-2698
15. Koopman M, Knijn N, Richman S, et al. The correlation between topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer Suppl 2009;7:321.
16. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-13091 (Pubitemid 351737597)
17. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005; 129:874-884 (Pubitemid 41242680)
18. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003;63:8791-8812 (Pubitemid 38064059)
19. Moreira MC, Barbot C, Tachi N, et al. The gene mutated in ataxiaocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet 2001;29:189-193 (Pubitemid 32952657)
20. Date H, Onodera O, Tanaka H, et al. Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet 2001;29:184-188 (Pubitemid 32952656)
21. Gueven N, Becherel OJ, Kijas AW, et al. Aprataxin, a novel protein that protects against genotoxic stress. Hum Mol Genet 2004;13: 1081-1093 (Pubitemid 38702194)
22. Mosesso P, Piane M, Palitti F, Pepe G, Penna S, Chessa L. The novel human gene aprataxin is directly involved in DNA single-strand-break repair. Cell Mol Life Sci 2005;62:485-491 (Pubitemid 40379238)
23. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82: 1107-1112 (Pubitemid 20213250)
24. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/ p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61: 4910-4915 (Pubitemid 32691909)
25. Arango D, Mariadason JM, Wilson AJ, et al. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-1765 (Pubitemid 37464151)
26. Ahel I, Rass U, El-Khamisy SF, et al. The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates. Nature 2006;443:713-716 (Pubitemid 44564716)
27. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
28. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456-467
29. Davalos V, Dopeso H, Castano J, et al. EPHB4 and survival of colorectal cancer patients. Cancer Res 2006;66:8943-8948 (Pubitemid 44521108)
30. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
31. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002;13:1841-1851 (Pubitemid 36040772)
32. Caldecott KW. Single-strand break repair and genetic disease. Nat Rev Genet 2008;9:619-631